| 14.03 0.11 (0.79%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 21.2 | 1-year : | 29.19 |
| Resists | First : | 18.15 | Second : | 25 |
| Pivot price | 12.84  |
|||
| Supports | First : | 7.07 | Second : | 5.89 |
| MAs | MA(5) : | 13.91 |
MA(20) : | 11.89 |
| MA(100) : | 7.24 |
MA(250) : | 4.04 |
|
| MACD | MACD : | 1.3  |
Signal : | 1.2 |
| %K %D | K(14,3) : | 38.2 |
D(3) : | 38 |
| RSI | RSI(14): 75.8 |
|||
| 52-week | High : | 25 | Low : | 0.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VTYX ] has closed below upper band by 35.8%. Bollinger Bands are 160.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 14.08 - 14.13 | 14.13 - 14.19 |
| Low: | 13.83 - 13.89 | 13.89 - 13.96 |
| Close: | 13.92 - 14.02 | 14.02 - 14.12 |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Fri, 23 Jan 2026
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—VTYX, ALEX, RVYL, and FFWM - Morningstar
Thu, 22 Jan 2026
Ventyx Biosciences approves cash bonus awards for executives ahead of planned merger - Investing.com
Wed, 21 Jan 2026
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Wed, 21 Jan 2026
Halper Sadeh LLC Encourages SEE, VTYX, SNCY Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Mon, 19 Jan 2026
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 67.9 (%) |
| Shares Short | 7,290 (K) |
| Shares Short P.Month | 5,420 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.5 % |
| Return on Equity (ttm) | -45.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -9.42 |
| PEG Ratio | 0 |
| Price to Book value | 5.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|